European Companies Search Engine

EU funding (€25.4M): Connecting digital mobility assessment to clinical outcomes for regulatory and clinical endorsement Hor 1 Apr 2019 EU Research and Innovation programme "Horizon"

Overview

Text

Connecting digital mobility assessment to clinical outcomes for regulatory and clinical endorsement

Optimal treatment of the impaired mobility resulting from ageing and chronic disease is one of the 21st century's greatest challenges facing patients, society, governments, healthcare services, and science. New interventions are a key focus. However, to accelerate their development, we need better ways to detect and measure mobility loss. Digital technology, including body worn sensors, has the potential to revolutionise mobility assessment. The overarching objectives of MOBILISE-D are threefold: to deliver a valid solution (consisting of sensor, algorithms, data analytics, outcomes) for real-world digital mobility assessment; to validate digital outcomes in predicting clinical outcome in chronic obstructive pulmonary disease, Parkinson’s disease, multiple sclerosis, proximal femoral fracture recovery and congestive heart failure; and, to obtain key regulatory and health stakeholder approval for digital mobility assessment. The objectives address the call directly by linking digital assessment of mobility to clinical endpoints to support regulatory acceptance and clinical practice. MOBILISE-D consists of 35 partners from 13 countries with long, successful collaboration, combining the requisite expertise to address the technical and clinical challenges. To achieve the objectives, partners will jointly develop and implement a digital mobility assessment solution to demonstrate that real-world digital mobility outcomes can successfully predict relevant clinical outcomes and provide a better, safer and quicker way to arrive at the development of innovative medicines. MOBILISE-D's results will directly facilitate drug development, and establish the roadmap for clinical implementation of new, complementary tools to identify, stratify and monitor disability, so enabling widespread, cost-effective access to optimal clinical mobility management through personalised healthcare.


Funded Companies:

Company name Funding amount
Alma Mater Studiorum - Universita Di Bologna €855,665
Amgen €0.00
Amgen Ltd. €0.00
Astrazeneca AB €0.00
Bayer AG €0.00
Centre Hospitalier Universitaire Montpellier €464,685
Christian-Albrechts-Universitaet ZU Kiel €1,072,069
Ecole Polytechnique Federale DE Lausanne €993,625
Eresearch Technology Inc. €0.00
Friedrich-Alexander-Universitaet Erlangen-Nuernberg €897,864
Fundacion Privada Instituto de Salud Global Barcelona €1,614,656
Grunenthal GmbH €0.00
Icon Clinical Research Ltd. €0.00
Imperial College of Science Technology and Medicine €390,540
Ixscient Ltd. €464,000
Katholieke Universiteit Leuven €831,661
Mcroberts B.V. €519,021
Merck KGaA €0.00
Norges Teknisk-Naturvitenskapelige Universitet Ntnu €2,261,649
Novartis Pharma AG €0.00
Pfizer Ltd. €0.00
Robert Bosch Gesellschaft FUR Medizinische Forschung mbH €2,432,796
Sanofi-Aventis Recherche & Developpement €0.00
Sheffield Teaching Hospitals NHS Foundation Trust €0.00
Takeda Development Centre Europe Ltd. €0.00
Takeda Pharmaceuticals International AG €0.00
Teva Pharmaceutical Industries Ltd. €0.00
THE Foundation FOR Medical Research Infrastructural Development AND Health Services Next TO THE Medical Center TEL Aviv €1,117,625
The Newcastle Upon Tyne Hospitals NHS Foundation Trust €0.00
The University of Sheffield €2,092,966
Universita Degli Studi Di Sassari €428,750
Universitatsklinikum Erlangen €1,125,055
Universitat Zurich €532,500
Universita Vita-Salute SAN Raffaele €704,105
University College Dublin, National University of Ireland, Dublin €1,551,550
University of Newcastle Upon Tyne €3,816,442
University of Northumbria AT Newcastle €432,261
Velocity Clinical Research Grosshansdorf GmbH €796,413

Source: https://cordis.europa.eu/project/id/820820

The filing refers to a past date, and does not necessarily reflect the current state.